Base de dados : MEDLINE
Pesquisa : D03.633.100.759.646.616.400 [Categoria DeCS]
Referências encontradas : 253 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 26 ir para página                         

  1 / 253 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29244925
[Au] Autor:Zadnipryanyy IV; Tretiakova OS; Sataieva TP
[Ti] Título:Cardio and cytoprotective effect of cytoflavin in terms of experimental perinatal hemic hypoxia.
[So] Source:Patol Fiziol Eksp Ter;60(4):64-71, 2016 Oct-Dec.
[Is] ISSN:0031-2991
[Cp] País de publicação:Russia (Federation)
[La] Idioma:eng
[Ab] Resumo:The purpose: The purpose of research is to study cardiocytoprotective effect of cytoflavin in terms of aperinatal hypoxia in experiment. Methods: During research the offspring (22 pups) of 15 females of white Wistar line rats aged 3-4 months were involved. The hypoxia was recreated by daily intraperitoneal introduction of sodium nitrite (NaNO2) in a dose of 5 mg/100 g of the body weight causing a moderately severe hypoxia. To females of the first group, and also their posterity medicamental correction wasn't carried out. To females of the second group (8 females) after administration of sodium nitrite Cytoflavin was injected intraperitoneally. For an assessment of consequences of a perinatal hypoxia pups aged 7 days were slaughtered by means of a fast decapitation under ethereal anesthesia. Results: It is taped that the hypoxia induced by nitrobonds has the expressed damaging effect on cardiomyocytes of newborn infant rats which is shown in the form of the hypoxemic and ischemic changes caused, first of all, by disturbance of integrity of cellular and mitochondrial membranes causes formation of hypoxemic type of a metabolism in a cardiac muscle, disturbance of energy balance in it found reflection in disturbance of automatism of a myocardium of experimental animals. Cytoflavin at pregnant females in experiment allows to lower a damage rate of cardiomyocytes at newborn animals, first of all, at the expense of his protective properties. Conclusion: Membrane-protective properties of the drug along with its anti-hypoxic and antioxidant effects can put Cytoflavin in a number of promising drugs with cardiological and cytological protective action, leading to the optimization of energy metabolism in ischemic myocardium and allows it to take its rightful place among the modern drugs which are used to correct disorders of energy metabolism in the ischemic myocardium including pathologies in the neonatal period.
[Mh] Termos MeSH primário: Cardiotônicos/farmacologia
Mononucleotídeo de Flavina/farmacologia
Hipóxia
Inosina Difosfato/farmacologia
Miocárdio
Miócitos Cardíacos
Niacinamida/farmacologia
Succinatos/farmacologia
[Mh] Termos MeSH secundário: Animais
Combinação de Medicamentos
Feminino
Hipóxia/induzido quimicamente
Hipóxia/tratamento farmacológico
Hipóxia/metabolismo
Hipóxia/patologia
Masculino
Miocárdio/metabolismo
Miocárdio/patologia
Miócitos Cardíacos/metabolismo
Miócitos Cardíacos/patologia
Ratos
Ratos Wistar
Nitrito de Sódio/efeitos adversos
Nitrito de Sódio/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cardiotonic Agents); 0 (Drug Combinations); 0 (Succinates); 0 (cytoflavin); 25X51I8RD4 (Niacinamide); 7N464URE7E (Flavin Mononucleotide); 86-04-4 (Inosine Diphosphate); M0KG633D4F (Sodium Nitrite)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180118
[Lr] Data última revisão:
180118
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  2 / 253 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28745667
[Au] Autor:Novikov AY; Kovalev VA; Vinichuk NV; Chernyh YA; Golub IE; Sorokina LV
[Ad] Endereço:Primorye regional clinical hospital #1, Vladivostok, Russia.
[Ti] Título:[Prevention and correction of cognitive dysfunction after general anesthesia].
[Ti] Título:Profilaktika i korrektsiia kognitivnykh narushenii posle obshchei anestezii..
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;117(6):28-31, 2017.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To evaluate clinical efficacy of intraoperative use of cytoflavin in the prevention and correction of cognitive functions in surgical patients with no history of neurological and psychosomatic disorders. MATERIAL AND METHODS: The study included 60 female patients who underwent surgery on the thyroid gland. Patients were stratified into two equal groups matched for main indices. Patients of the main group received infusions of cytoflavin (20 ml in 200 ml of 5% glucose solution). Patients underwent thyroidectomy with general inhalation anesthesia using desflurane. Cognitive testing was performed one day before operation and 6, 24 and 48 h after. Waking time after stopping desflurane administration and time prior tracheal extubation were recorded. RESULTS AND CONCLUSION: The use of cytoflavin promoted the early post anesthesia adaptation and more rapid recovery of initial cognitive status of the patients.
[Mh] Termos MeSH primário: Período de Recuperação da Anestesia
Anestesia por Inalação/efeitos adversos
Anestésicos Inalatórios/efeitos adversos
Disfunção Cognitiva/induzido quimicamente
Disfunção Cognitiva/prevenção & controle
Mononucleotídeo de Flavina/uso terapêutico
Inosina Difosfato/uso terapêutico
Niacinamida/uso terapêutico
Succinatos/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Anestésicos Inalatórios/administração & dosagem
Combinação de Medicamentos
Feminino
Seres Humanos
Cuidados Intraoperatórios
Isoflurano/administração & dosagem
Isoflurano/efeitos adversos
Isoflurano/análogos & derivados
Meia-Idade
Doenças da Glândula Tireoide/cirurgia
Tireoidectomia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anesthetics, Inhalation); 0 (Drug Combinations); 0 (Succinates); 0 (cytoflavin); 25X51I8RD4 (Niacinamide); 7N464URE7E (Flavin Mononucleotide); 86-04-4 (Inosine Diphosphate); CRS35BZ94Q (desflurane); CYS9AKD70P (Isoflurane)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro20171176128-31


  3 / 253 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28574379
[Au] Autor:Skrypko V; Kovalenko A; Zaplutanov V; Kharitonova T; Myhaloyko I
[Ad] Endereço:1Ivano-Frankivsk National Medical University, Ukraine; 2Institute of Toxicology of Federal Medical-Biology Agency, Saint-Petersburg, Russia; 3I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry of Russian Academy of Sciences, Saint-Petersburg, Russia; 4Saint-Petersburg I. I. Dzhaneli
[Ti] Título:[EFFICACY OF CYTOFLAVIN IN COMPLEX TREATMENT OF DIABETIC FOOT SYNDROME].
[So] Source:Georgian Med News;(265):14-19, 2017 Apr.
[Is] ISSN:1512-0112
[Cp] País de publicação:Georgia (Republic)
[La] Idioma:rus
[Ab] Resumo:The study involved 97 patients with severe diabetic foot syndrome (DFS) subcompensated type 2 diabetes. All patients were available mediacalcification foot and lower leg arteries of different severity. Depending on the treatment, all patients were divided into 2 groups by stratified randomization. The І group received standard therapy, which is indicated for the DFS. A ІІ group of patients additionally received basic therapy drug Cytoflavin 10 ml 0,9% NaCl 200 ml for 10 days, followed by transfer to tablet form Cytoflavin 2 tablets 2 times per day orally for one month. We noted a positive trend of treatment of patients who, in addition to standard therapy received the drug Cytoflavin. Thus, the use of complex surgical treatment of patients with mixed form of DFS Cytoflavin reduces the severity of distal polyneuropathy, improves oxygenation of tissues and restores the enzyme activity of antioxidant system, that manifested neuroprotective, antioxidant and anti-hypoxic effects of drugs, which substantiates the indications for its use in the this pathology.
[Mh] Termos MeSH primário: Antioxidantes/uso terapêutico
Diabetes Mellitus Tipo 2/tratamento farmacológico
Pé Diabético/tratamento farmacológico
Mononucleotídeo de Flavina/uso terapêutico
Inosina Difosfato/uso terapêutico
Fármacos Neuroprotetores/uso terapêutico
Niacinamida/uso terapêutico
Succinatos/uso terapêutico
[Mh] Termos MeSH secundário: Terapia Combinada
Diabetes Mellitus Tipo 2/complicações
Pé Diabético/etiologia
Pé Diabético/cirurgia
Combinação de Medicamentos
Feminino
/irrigação sanguínea
Seres Humanos
Perna (Membro)/irrigação sanguínea
Masculino
Esclerose Calcificante da Média de Monckeberg/complicações
Esclerose Calcificante da Média de Monckeberg/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antioxidants); 0 (Drug Combinations); 0 (Neuroprotective Agents); 0 (Succinates); 0 (cytoflavin); 25X51I8RD4 (Niacinamide); 7N464URE7E (Flavin Mononucleotide); 86-04-4 (Inosine Diphosphate)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170603
[St] Status:MEDLINE


  4 / 253 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28399094
[Au] Autor:Mazin PV; Sheshunov IV; Mazina NK
[Ad] Endereço:Kirov State Medical University, Kirov, Russia.
[Ti] Título:[Meta-analytic assessment of parenteral cytoflavin effectiveness in different neurologic disorders].
[Ti] Título:Metaanaliticheskaia otsenka klinicheskoi éffektivnosti tsitoflavina pri nevrologicheskikh zabolevaniiakh..
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;117(3):28-39, 2017.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To carry out an integral quantitative assessment of the clinical efficacy of parenteral use of cytoflavin in treatment of patients with CNS disorders based on the systemic selection of published controlled clinical trials and their meta-analysis. MATERIAL AND METHODS: Twenty-one high evidence-based studies on the efficacy of parenteral use of cytoflavin in different CNS disorders (4314 patients) have been analyzed. Comparisons with basic treatment groups were undertaken to clarify the drug clinical effects adjusted for heterogeneity and variability of response parameters. RESULTS AND CONCLUSION: An analysis of formalized efficacy indicators (increase in the absolute and relative value, odds ratio (OR) etc.) has demonstrated the advantages of cytoflavin. Group combination has increased the statistical power of the meta-analysis. Two models with fixed (Mantel-Haenszel amendment) and random effects were used. All the estimation protocols in different clinical groups of patients with neurologic diseases provided similar results and confirmed the stability of calculated values irrespective of heterogeneity of data arrays. OR of positive outcomes in neuropathologies treated with cytoflavin was 3,02 with χ2 heterogeneity 427,3 and p = 0,000…, I2= 85,7% (82%; 88%).
[Mh] Termos MeSH primário: Doenças do Sistema Nervoso Central/tratamento farmacológico
Mononucleotídeo de Flavina/uso terapêutico
Inosina Difosfato/uso terapêutico
Niacinamida/uso terapêutico
Succinatos/uso terapêutico
[Mh] Termos MeSH secundário: Combinação de Medicamentos
Mononucleotídeo de Flavina/administração & dosagem
Seres Humanos
Infusões Parenterais
Inosina Difosfato/administração & dosagem
Niacinamida/administração & dosagem
Succinatos/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Succinates); 0 (cytoflavin); 25X51I8RD4 (Niacinamide); 7N464URE7E (Flavin Mononucleotide); 86-04-4 (Inosine Diphosphate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro20171173128-39


  5 / 253 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28374695
[Au] Autor:Sazonov IE; Kudinov AA; Fedotova EP
[Ad] Endereço:Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia; Voronezh City Clinical Emergency Hospital #1, Voronezh, Russia.
[Ti] Título:[Study cytoflavin dose-dependent effect in the treatment of acute ischemic stroke].
[Ti] Título:Izuchenie dozozavisimogo effekta tsitoflavina v terapii ostrogo perioda ishemicheskogo insul'ta..
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;117(2):64-67, 2017.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To compare the efficacy of cytoflavin in doses of 10 and 20 ml/day in the complex pharmacological therapy of patients with acute ischemic stroke. MATERIAL AND METHODS: Eighty-six patients, aged from 43 to 85 years, were examined. Patient's status was assessed using the NIHSS, the Rankin scale, the Barthel index and the Rivermead mobility index. Patients were stratified into 3 groups: patients of group 1 received standard treatment, patients of group 2 received cytoflavin in dose of 10 ml/day in addition to standard treatment and patients of group 3 were treated with cytoflavin in dose of 20 ml/day in addition to standard treatment. RESULTS AND CONCLUSION: Cytoflavin in doses of 10 and 20 ml/day significantly promotes the regression of neurological deficit, improves day-to-day activity, and therefore, improves functional independence in daily life. The dose-dependent effect of the drug was shown. The use of cytoflavin in dose of 20 ml/day resulted in the more rapid regress of neurological symptoms during inpatient treatment and higher indices of daily activities and functional independence of patients that was important for the further rehabilitation.
[Mh] Termos MeSH primário: Mononucleotídeo de Flavina/administração & dosagem
Inosina Difosfato/administração & dosagem
Niacinamida/administração & dosagem
Acidente Vascular Cerebral/tratamento farmacológico
Succinatos/administração & dosagem
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Relação Dose-Resposta a Droga
Combinação de Medicamentos
Feminino
Hospitalização
Seres Humanos
Masculino
Meia-Idade
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Succinates); 0 (cytoflavin); 25X51I8RD4 (Niacinamide); 7N464URE7E (Flavin Mononucleotide); 86-04-4 (Inosine Diphosphate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170810
[Lr] Data última revisão:
170810
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro20171172164-67


  6 / 253 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27635609
[Au] Autor:Karakulova YV; Selyanina NV; Zhelnin AV; Filimonova TA; Cepilov SV
[Ad] Endereço:Vagner Perm State Medical University, Perm, Russia.
[Ti] Título:[Effect of antioxidant therapy on neurotrophins and processes of rehabilitation after stroke].
[Ti] Título:Vliyanie antioksidantnoi terapii na neirotrofiny i protsessy reabilitatsii posle insul'ta..
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;116(8):36-39, 2016.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The aim of the research was to study the effect of the inclusion in the scheme cytoflavin patient care during the recovery period of ischemic stroke in the neuropsychological changes in the status and content of neurotrophins in serum. For this purpose we surveyed 52 patients who underwent a first ischemic stroke (29 women and 23 men) aged 52-74 years. Patients were divided into 2 groups: primary (25 patients) received in addition to basic therapy cytoflavin: intravenously at 20 ml per 400 ml of 5% glucose solution, 1 time a day for 10 days, then into 2 tablets 2 times a day for half an hour before food for a month, and the comparison group (27 patients) who received standard treatment. The control group consisted of 12 healthy people. In addition to standard clinical and laboratory tests were carried out a comprehensive neuropsychological study and evaluation of the data on the scale NIHSS, Bartell, Beck, Spielberger-Hanin, test «frontal dysfunction of the battery¼ and the Mini-Mental State Examination. Furthermore, determination carried neurotrophic factors: nerve growth factor (NGF) and brain-derived neurotrophic factor brain (BDNF). The study was conducted in the dynamics: before treatment and 2 months after treatment. Patients in the recovery period of the first ischemic stroke revealed moderate manifestations of neuropsychological disorders status and reduction of neurotrophic factors. Inclusion in cytoflavin scheme increased the efficiency of the treatment, which was manifested in a more pronounced when compared with the results of basic therapy, positive dynamics of neurological symptoms and improved cognitive function, accompanied by an increase in BDNF levels. The data on the efficacy and safety allow us to recommend its inclusion in the scheme of treatment of patients in the recovery period after the first carotid ischemic stroke.
[Mh] Termos MeSH primário: Antioxidantes/uso terapêutico
Fator Neurotrófico Derivado do Encéfalo/sangue
Mononucleotídeo de Flavina/uso terapêutico
Inosina Difosfato/uso terapêutico
Fator de Crescimento Neural/sangue
Niacinamida/uso terapêutico
Reabilitação do Acidente Vascular Cerebral/métodos
Acidente Vascular Cerebral/tratamento farmacológico
Succinatos/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Combinação de Medicamentos
Feminino
Seres Humanos
Masculino
Meia-Idade
Acidente Vascular Cerebral/sangue
Resultado do Tratamento
[Pt] Tipo de publicação:CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Brain-Derived Neurotrophic Factor); 0 (Drug Combinations); 0 (Succinates); 0 (brain-derived neurotrophic factor, human); 0 (cytoflavin); 25X51I8RD4 (Niacinamide); 7N464URE7E (Flavin Mononucleotide); 86-04-4 (Inosine Diphosphate); 9061-61-4 (Nerve Growth Factor)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160917
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro20161168136-39


  7 / 253 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27459489
[Au] Autor:Skripkо VD; Pasko AJ; Kovalenko AL; Zaplutanov VA
[Ad] Endereço:Ivano-Frankivsk National Medical University, 76018 Ivano-Frankivsk, street. Galician, 2, Ukraine.
[Ti] Título:[Cytoflavin rationale for the use in treatment of patients with postsurgical hypothyroidism].
[Ti] Título:Obosnovanie primeneniya tsitoflavina v kompleksnom lechenii bol'nykh s posleoperatsionnym gipoparatireozom..
[So] Source:Khirurgiia (Mosk);(7):53-57, 2016.
[Is] ISSN:0023-1207
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The aim of the study was to assess the effectiveness of cytoflavin inclusion in complex treatment of patients with hypoparathyroidism occurring after thyroid surgery. To do this, an analysis of treatment of 54 patients who received surgical treatment for thyroid diseases of various etiologies. Depending on the scheme of post-operative medical therapy, the patients were divided into 2 groups: group I patients (27 persons) received basic therapy according to regulatory documents, II of the group (27 patients) in addition cytoflavin intravenous drip of 10 ml to 200 ml 0.9% NaCl for 7 days. In addition to standard clinical and laboratory examination, all patients were studied and the level of active ionized Ca2+ and PTH, oxidation products of the modified protein, lipid peroxidation and antioksidazation system dynamics - 1, 3 and 7 days after surgery. It was revealed that in the first days after the surgical treatment of patients significantly reduced the levels of ionized Ca2+ and PTH that may be regarded as signs of postoperative hypoparathyroidism, as well as the activation of the system of lipid peroxidation and antioxidant system depression. Turning cytoflavin in drug regimens improved the efficiency of the treatment, which was manifested in arresting to 7 days of monitoring signs of hypoparathyroidism, improve tissue oxygenation and restoring the balance by reducing the activity of the system of lipid peroxidation and antioxidant system strengthening.
[Mh] Termos MeSH primário: Mononucleotídeo de Flavina/administração & dosagem
Hipotireoidismo
Inosina Difosfato/administração & dosagem
Peroxidação de Lipídeos/efeitos dos fármacos
Niacinamida/administração & dosagem
Oxirredução/efeitos dos fármacos
Complicações Pós-Operatórias
Succinatos/administração & dosagem
Doenças da Glândula Tireoide/cirurgia
Tireoidectomia/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Cálcio/sangue
Combinação de Medicamentos
Monitoramento de Medicamentos/métodos
Feminino
Seres Humanos
Hipotireoidismo/sangue
Hipotireoidismo/diagnóstico
Hipotireoidismo/etiologia
Infusões Intravenosas
Masculino
Meia-Idade
Fármacos Neuroprotetores/administração & dosagem
Hormônio Paratireóideo/sangue
Complicações Pós-Operatórias/diagnóstico
Complicações Pós-Operatórias/tratamento farmacológico
Estudos Retrospectivos
Tireoidectomia/métodos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Neuroprotective Agents); 0 (Parathyroid Hormone); 0 (Succinates); 0 (cytoflavin); 25X51I8RD4 (Niacinamide); 7N464URE7E (Flavin Mononucleotide); 86-04-4 (Inosine Diphosphate); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160727
[St] Status:MEDLINE
[do] DOI:10.17116/hirurgia2016753-57


  8 / 253 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27239991
[Au] Autor:Ashour АZ; Belov VG; Parfyonov UA; Parfyonov SA; Ershov EV; Tuchin IA; Kovalenko AL; Talikova EV
[Ad] Endereço:St. Petersburg Institute of Bioregulation and Gerontology, St. Petersburg, Russia.
[Ti] Título:[The effectiveness of the combined use of energomonitor antioxidant and cognitive psychotherapy in the treatment of generalized periodontitis in elderly patients].
[So] Source:Stomatologiia (Mosk);95(2):14-17, 2016.
[Is] ISSN:0039-1735
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The aim of the study was to evaluate the effect of combined use of Cytoflavin and cognitive therapy on the dynamics of psychosomatic status and effectiveness of the treatment of generalized periodontitis in elderly patients. The results of treatment of 103 patients aged 60 and older were analyzed. All patients received standard therapy for 10-14 days depending on the severity of the process. In addition, the patients of the main group (51 patients) received Cytoflavin: 2 tabs. 2 times a day with an interval between doses of 8-10 hours for 25 days, and cognitive therapy aimed at training alternative realistic way of life perception. Treatment results were monitored by PMA, Russell periodontal index (PI), Green-Vermillion hygienic index. Psychosomatic dynamics was assessed by means of Spielberger anxiety scale and SUN" methods of before and after a month of treatment. The inclusion in the treatment regimen of Cytoflavin and cognitive therapy had a positive impact: reduction of PMA by 61.8%, PI by 45.3% and Green-Vermillion index by 39.8%. The psychosomatic tests proved anxiety level decrease by 28.7% in terms of "reactive" anxiety and 31.5% in terms of "personal" anxiety, emotional status (21.2%), activity (21.7%) and mood (21.8%) improvement.
[Mh] Termos MeSH primário: Antioxidantes/uso terapêutico
Terapia Cognitiva
Mononucleotídeo de Flavina/uso terapêutico
Inosina Difosfato/uso terapêutico
Niacinamida/uso terapêutico
Periodontite/terapia
Succinatos/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Terapia Combinada
Combinação de Medicamentos
Seres Humanos
Meia-Idade
Periodontite/tratamento farmacológico
Periodontite/psicologia
Resultado do Tratamento
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antioxidants); 0 (Drug Combinations); 0 (Succinates); 0 (cytoflavin); 25X51I8RD4 (Niacinamide); 7N464URE7E (Flavin Mononucleotide); 86-04-4 (Inosine Diphosphate)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:160531
[St] Status:MEDLINE
[do] DOI:10.17116/stomat201695214-17


  9 / 253 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27239928
[Au] Autor:Belova LA; Mashin VV; Kolotik-Kameneva OY; Belova NV
[Ad] Endereço:Ulyanovsk State University, Ministry of Health of Russia, Ulyanovsk, Russia.
[Ti] Título:[Effect of cytoflavin on the clinical and autonomic-psychological manifestations of hypertensive disease].
[So] Source:Ter Arkh;88(5):55-61, 2016.
[Is] ISSN:0040-3660
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To evaluate the impact of incorporating cytoflavin in a treatment regimen for patients with different stages of hypertensive disease (HD). SUBJECTS AND METHODS: The results of treatment were analyzed in 140 patients with HD (53 with Stage I, 50 with Stage II, and 37 with Stage III). According to the treatment regimen, the patients were divided into 2 groups. A study group (n=74) received combination treatment involving antihypertensive therapy and cytoflavin intravenously dropwisely in a single dose of 200 ml of 5% glucose solution for 10 days, then 2 tablets twice daily for 60 days, with a total cycle time being 70 days. A comparison group (n=66) had antihypertensive therapy only. Thirty apparently healthy individuals (a control group) were examined to have reference values. All the patients were examined using conventional clinical and laboratory studies. The patients' complaints and neurological status were assessed using respective questionnaires over time - before and after treatment. RESULTS: The incorporation of cytoflavin in a treatment regimen was ascertained to reduce the degree of anxiety, depressive, dissomnic, and cognitive disorders, improves quality of life in patients with Stage I HD, and lowers the degree of asthenic and autonomic disorders in all disease stages. CONCLUSION: The found efficacy and safety of the drug may recommend its incorporation in combination therapy regimens for Stages I-III HD.
[Mh] Termos MeSH primário: Anti-Hipertensivos/farmacologia
Ansiedade/tratamento farmacológico
Doenças do Sistema Nervoso Autônomo/tratamento farmacológico
Transtornos Cognitivos/tratamento farmacológico
Depressão/tratamento farmacológico
Mononucleotídeo de Flavina/farmacologia
Hipertensão/tratamento farmacológico
Inosina Difosfato/farmacologia
Niacinamida/farmacologia
Succinatos/farmacologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Anti-Hipertensivos/administração & dosagem
Combinação de Medicamentos
Quimioterapia Combinada
Feminino
Mononucleotídeo de Flavina/administração & dosagem
Seres Humanos
Inosina Difosfato/administração & dosagem
Masculino
Meia-Idade
Niacinamida/administração & dosagem
Índice de Gravidade de Doença
Succinatos/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Drug Combinations); 0 (Succinates); 0 (cytoflavin); 25X51I8RD4 (Niacinamide); 7N464URE7E (Flavin Mononucleotide); 86-04-4 (Inosine Diphosphate)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160531
[St] Status:MEDLINE
[do] DOI:10.17116/terarkh201688555-61


  10 / 253 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27220241
[Au] Autor:Bazhanova ED; Kozlova YO; Anisimov VN; Sukhanov DS; Teply DL
[Ti] Título:[PHARMACOLOGICAL CORRECTION OF APOPTOSIS LEVEL OF CORTICAL NEURONS IN AGED HER2/NEU TRANSGENIC MICE].
[So] Source:Zh Evol Biokhim Fiziol;52(1):58-66, 2016 Jan-Feb.
[Is] ISSN:0044-4529
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Neurodegenerative changes and neuronal death are the basis for development of the nervous system aging. We investigated the mechanism of apoptosis of the sensorimotor cortex neurons of transgenic mice HER2/neu during aging, changes in the cortex function and the participation of exogenous neurometabolites (cytoflavin, piracetam) in regulation of neuronal death and locomotor and psycho-emotional status of mice. The level of apoptosis and expression of apoptosis markers (TUNEL, immunohistochemistry, Western blotting) in HER2/neu transgenic mice as compared to wild type mice (FBV line) were determined. In aging FBV mice the basal activity was shown to decrease and anxiety to increase correlating with the high level of neuronal apoptosis. We identified behavioral characteristics of transgenic HER2/neu mice and found that their low basal activity does not change with aging. Previously we have shown that in this strain of mice the apoptosis level is low, without any age-related changes, due to the suppression, first of all, of the p53-dependent pathway by HER2 (tyrosine kinase receptor) overexpression. Cytoflavin and piracetam were revealed to possess a marked neuroprotective effect, preserving and restoring functions of the nervous system (improving locomotion and psychological status) in both strains of mice. The effect of neurometabolites studied on neuronal apoptosis is ambiguous. In case of its low level it is a moderate stumulation of apoptosis via the external p53-dependent pathways with activation of caspase-3 in transgenic HER2/neu mice with high carcinogenesis level that can possibly prevent tumor development. On the contrary, in old wild-type animals we observed a significant decrease of age-dependent apoptosis level (by stimulating expression of the anti-apoptotic protein Mcl-1), which prevents neurodegeneration.
[Mh] Termos MeSH primário: Córtex Cerebral/efeitos dos fármacos
Mononucleotídeo de Flavina/farmacologia
Inosina Difosfato/farmacologia
Neurônios/efeitos dos fármacos
Fármacos Neuroprotetores/farmacologia
Niacinamida/farmacologia
Piracetam/farmacologia
Receptor ErbB-2/genética
Succinatos/farmacologia
[Mh] Termos MeSH secundário: Animais
Apoptose
Córtex Cerebral/citologia
Córtex Cerebral/crescimento & desenvolvimento
Combinação de Medicamentos
Camundongos
Neurônios/metabolismo
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Neuroprotective Agents); 0 (Succinates); 0 (cytoflavin); 25X51I8RD4 (Niacinamide); 7N464URE7E (Flavin Mononucleotide); 86-04-4 (Inosine Diphosphate); EC 2.7.10.1 (Erbb2 protein, mouse); EC 2.7.10.1 (Receptor, ErbB-2); ZH516LNZ10 (Piracetam)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:160525
[Lr] Data última revisão:
160525
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160526
[St] Status:MEDLINE



página 1 de 26 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde